ESTRO 2024 - Abstract Book

S2580

Clinical - Urology

ESTRO 2024

Conclusion:

Salvage re-EBRT for isolated relapse of PCa in prostatic bed is an option as salvage treatment, especially in order to procrastinate systemic therapies as hormone therapy, however, correct doses and timing of re-EBRT should be furtherly investigated.

Keywords: Reirradiation, prostate, toxicity

2858

Digital Poster

Role of SBRT in patients with metastatic renal carcinoma: experience in our center

JOSEP GARRE CRISTAU 1 , Diego Gómez-Puerto 1 , Abraham A.A Geng-Cahyaume 1 , Manuel Altabas 2 , David Marmolejo Castañeda 3 , Alejandra Rezqallag-Arón 2 , Rafael Morales-Barrera 2 , Macarena Gonzalez 2 , Joan Carles Galceran 4 , Cristina Suarez 4 , Xavier Maldonado-Pijoan 2 1 Hospital Universitari Vall d'Hebron, Radiation Oncology, Barcelona, Spain. 2 Hospital, Radiation Oncology, Barcelona, Spain. 3 Hospital, Radiation Oncology, Barelona, Spain. 4 Hospital, Radiation Oncology, barcelona, Spain

Purpose/Objective:

The role of radiotherapy in metastatic renal cell carcinoma (RCC) is changing recently, since the scenario of oligometastatic disease (OM) and oligoprogression (OP) is increasing. RCC was historically considered radioresistant, but SBRT may alter this paradigm, with data of favourable local control (LC) ≥90% in literature. Even though the benefit of SBRT on event-free survival (EFS) and overall survival (OS) are still not well defined, we retrospectively described the experience we had in our centre with oligometastatic/oligoprogressive RCC patients treated with SBRT.

Material/Methods:

We analysed patients with confirmed RCC and extracranial metastatic lesions treated with SBRT planning (defined as ≥5 Gy per fraction in ≤5 fractions) as definitive treatment, and maintained without systemic treatment, at Vall d'Hebron Hospital between 2019 and 2022. A descriptive analysis was performed including clinicopathological, demographic and therapeutic variables, including the SBRT plan performed. Time to next treatment (TTNT) and time free of systemic treatment (TFST), 6-month and 1-year EFS rate, and OS at 1 year of SBRT treatment were obtained.

Results:

Thirty-three patients were included (33.3% female, 66.6% male, median age: 61.3). 81.8% patients had been nephrectomised, and 81.8% was clear cell histology and 9.1% papillary.